As part of a joint interview with Nicolas Violle, CEO of ETAP-LAB, and Sophie Hidalgo, Head of Animal Facilities and Animal Welfare across our three sites, Gircor highlights the key challenges faced by Contract Research Organizations (CROs) in preclinical drug development.<\/p>\n\n\n\n
In a context where societal expectations, regulatory frameworks, and scientific standards are rapidly evolving, organizations like ETAP-LAB play a critical role in balancing therapeutic innovation, scientific rigor, and ethical responsibility.<\/p>\n\n\n\n
\n\u201cEthology has been at the core of our practices for over 35 years.\u201d<\/strong> \u2014 Nicolas Violle, CEO, ETAP-LAB<\/p>\n\n\n\n
<\/div>\n\n\n\nA Science-Driven and Responsible Approach to Preclinical Models<\/h2>\n\n\n\n
In this interview, ETAP-LAB shares its vision of responsible research, particularly in the use of rodent models in neurology (including stroke), cardiology, and dermatology.<\/p>\n\n\n\n
The company is actively committed to:<\/p>\n\n\n\n
\n
- integrating animal welfare into scientific quality<\/li>\n\n\n\n
- rigorously applying the principles of the 3Rs (Replace, Reduce, Refine)<\/strong><\/li>\n\n\n\n
- developing innovative R&D programs aimed at reducing and replacing animal models<\/strong><\/li>\n<\/ul>\n\n\n\n
<\/div>\n\n\n\nAccelerating the Shift Toward Alternative Methods<\/h2>\n\n\n\n
ETAP-LAB is also engaged in advancing and implementing alternative approaches, including New Approach Methodologies (NAMs)<\/strong> and organ-on-chip technologies<\/strong>, which are expected to play an increasing role in the future of biomedical research.<\/p>\n\n\n\n
While these methods are progressing, their broader adoption still depends on validation and regulatory acceptance.<\/p>\n\n\n\n
The challenge is two fold:<\/p>\n\n\n\n
\n
- accelerate the development and recognition of alternatives<\/strong><\/li>\n\n\n\n
- while continuously improving practices when animal models remain necessary<\/strong><\/li>\n<\/ul>\n\n\n\n
<\/div>\n\n\n\nThe Strategic Role of CROs in the Evolving Landscape<\/h2>\n\n\n\n
This interview highlights the pivotal role of CROs in drug development, at the intersection of academic research, the pharmaceutical industry, and regulatory requirements.<\/p>\n\n\n\n
It also emphasizes the importance of transparency<\/strong> and public dialogue\u2014key missions of Gircor<\/a>.<\/p>\n\n\n\n
<\/div>\n\n\n\nRead the Full Interview<\/h2>\n\n\n\n
To learn more and explore the full discussion (French version only):<\/strong><\/p>\n\n\n\n
\ud83c\udf99\ufe0fLes d\u00e9fis d’une CRO dans l’\u00e9valuation pr\u00e9clinique du m\u00e9dicament<\/a><\/blockquote>